Mazen Noureddin VIEW CLINICAL PROFILE

Mazen Noureddin, MD, MHSc

Professor of Medicine, Academic Institute
Full Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


VIEW CLINICAL PROFILE
Biography

Dr. Noureddin completed his internal medicine residency at the University of Southern California (USC) and then moved to the National Institutes of Health (NIH), where he enrolled in a three-year hepatology fellowship at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). At NIH, he completed the NIH/Duke University Master of Health Sciences in Clinical Research program. After completing his NIH fellowship, he completed a gastroenterology fellowship at the University of California, San Diego (UCSD), where he was a T32 NIH fellow. He then joined the University of Southern California (USC) as an Assistant Professor of Clinical Medicine in 2013.  He was then recruited to Cedars-Sinai Medical Center in 2015 to establish its new fatty liver program. In 2022, he relocated to Texas to establish a state-of-the-art research institute. 

Publications

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-related advanced fibrosis and cirrhosis in the United States population utilizing AGILE 3 + and AGILE 4 scores: analysis of the NHANES 2017–2018 cycle
Alkhouri, N, Almomani, A, Le, P, Payne, JY, Asaad, I, Polanco, P, Leff, P, Kumar, P & Noureddin, M 2024, , BMC Gastroenterology, vol. 24, no. 1, 218. https://doi.org/10.1186/s12876-024-03295-8

Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019
Danpanichkul, P, Suparan, K, Dutta, P, Kaeosri, C, Sukphutanan, B, Pang, Y, Kulthamrongsri, N, Jaisa-aad, M, Ng, CH, Teng, M, Nakano, M, Morishita, A, Alkhouri, N, Yang, JD, Chen, VL, Kim, D, Fallon, MB, Diaz, LA, Arab, JP, Mantzoros, CS, Noureddin, M, Lazarus, JV & Wijarnpreecha, K 2024, , Metabolism: Clinical and Experimental, vol. 158, 155958, pp. 155958. https://doi.org/10.1016/j.metabol.2024.155958

Sex-based Disparities in Liver Transplantation for Hepatocellular Carcinoma and the Impact of the Growing Burden of NASH
Koh, JH, Chee, D, Ng, CH, Wijarnpreecha, K, Muthiah, M, Tan, DJH, Lim, WH, Zeng, RW, Koh, B, Xuan, ETX, Bonney, G, Iyer, S, Young, DY, Nakamura, T, Takahashi, H, Noureddin, M, Siddiqui, MS, Simon, TG, Loomba, R & Huang, DQ 2024, , Transplantation Direct, vol. 10, no. 7, e1642. https://doi.org/10.1097/TXD.0000000000001642

Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity
Chan, WK, Petta, S, Noureddin, M, Goh, GBB & Wong, VWS 2024, , Alimentary Pharmacology and Therapeutics, vol. 59, no. S1, pp. S23-S40. https://doi.org/10.1111/apt.17866

The Burden of Overweight and Obesity-Associated Gastrointestinal Cancers in Low and Lower-Middle-Income Countries: A Global Burden of Disease 2019 Analysis
Danpanichkul, P, Auttapracha, T, Sukphutanan, B, Ng, CH, Wattanachayakul, P, Kongarin, S, Dutta, P, Duangsonk, K, Thongpiya, J, Muthiah, MD, Huang, DQ, Lui, RN, Seko, Y, Takahashi, H, Noureddin, M, Yang, JD, Wallace, MB & Wijarnpreecha, K 2024, , American Journal of Gastroenterology, vol. 119, no. 6, pp. 1177-1180. https://doi.org/10.14309/ajg.0000000000002819

From Shadows to Spotlight: Exploring the Escalating Burden of Alcohol-Associated Liver Disease and Alcohol Use Disorder in Young Women
Danpanichkul, P, Ng, CH, Muthiah, M, Suparan, K, Tan, DJH, Duangsonk, K, Sukphutanan, B, Kongarin, S, Harinwan, N, Panpradist, N, Takahashi, H, Kawaguchi, T, Vichitkunakorn, P, Chaiyakunapruk, N, Nathisuwan, S, Huang, D, Arab, JP, Noureddin, M, Mellinger, JL & Wijarnpreecha, K 2024, , American Journal of Gastroenterology, vol. 119, no. 5, pp. 893-909. https://doi.org/10.14309/ajg.0000000000002642

Use of non-invasive diagnostic tools for metabolic dysfunction-associated steatohepatitis: A qualitative exploration of challenges and barriers
Tsochatzis, EA, Valenti, L, Thiele, M, Péloquin, S, Lazure, P, Masson, MH, Allen, AM, Lazarus, JV, Noureddin, M, Rinella, M, Tacke, F & Murray, S 2024, , Liver International, vol. 44, no. 8, pp. 1990-2001. https://doi.org/10.1111/liv.15941

Global and regional burden of alcohol-associated liver disease and alcohol use disorder in the elderly
Danpanichkul, P, Suparan, K, Ng, CH, Dejvajara, D, Kongarin, S, Panpradist, N, Chaiyakunapruk, N, Muthiah, MD, Chen, VL, Huang, DQ, Díaz, LA, Noureddin, M, Arab, JP & Wijarnpreecha, K 2024, , JHEP Reports, vol. 6, no. 4, 101020, pp. 101020. https://doi.org/10.1016/j.jhepr.2024.101020

The Global Burden of Early-Onset Biliary Tract Cancer: Insight From the Global Burden of Disease Study 2019
Danpanichkul, P, Ng, CH, Tan, DJH, Muthiah, MD, Kongarin, S, Srisurapanont, K, Kanjanakot, Y, Duangsonk, K, Huang, DQ, Suzuki, H, Harnois, DM, Yang, JD, Noureddin, M & Wijarnpreecha, K 2024, , Journal of Clinical and Experimental Hepatology, vol. 14, no. 2, 101320, pp. 101320. https://doi.org/10.1016/j.jceh.2023.101320

Artificial intelligence in liver cancer research: a scientometrics analysis of trends and topics
Rezaee-Zavareh, MS, Kim, N, Yeo, YH, Kim, H, Lee, JM, Sirlin, CB, Taouli, B, Saouaf, R, Wachsman, AM, Noureddin, M, Wang, Z, Moore, J, Li, D, Singal, AG & Yang, JD 2024, , Frontiers in Oncology, vol. 14, 1355454, pp. 1355454. https://doi.org/10.3389/fonc.2024.1355454

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
MAESTRO-NASH Investigators 2024, , New England Journal of Medicine, vol. 390, no. 6, pp. 497-509. https://doi.org/10.1056/NEJMoa2309000

From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New
Alabdul Razzak, I, Noureddin, M & Trivedi, HD 2024, , Journal of Clinical Medicine, vol. 13, no. 3, 880. https://doi.org/10.3390/jcm13030880

Uncoupler therapy for NAFLD: is flushing a possible harbinger of a safety concern? – Authors' reply
Noureddin, M, Jorkasky, D, Khan, S & Sanyal, AJ 2024, , The Lancet Gastroenterology and Hepatology, vol. 9, no. 2, pp. 105-106. https://doi.org/10.1016/S2468-1253(23)00446-6

Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
Noureddin, M, Truong, E, Mayo, R, Martínez-Arranz, I, Mincholé, I, Banales, JM, Arrese, M, Cusi, K, Arias-Loste, MT, Bruha, R, Romero-Gómez, M, Iruzubieta, P, Aller, R, Ampuero, J, Calleja, JL, Ibañez-Samaniego, L, Aspichueta, P, Martín-Duce, A, Kushner, T, Ortiz, P, Harrison, SA, Anstee, QM, Crespo, J, Mato, JM & Sanyal, AJ 2024, , Hepatology, vol. 79, no. 1, pp. 135-148. https://doi.org/10.1097/HEP.0000000000000542

Learnings From the Graveyard of Phase 2 and 3 Nonalcoholic Steatohepatitis Trials
Francque, SM, Noureddin, M & Krag, A 2024, , Clinical Gastroenterology and Hepatology, vol. 22, no. 1, pp. 16-19. https://doi.org/10.1016/j.cgh.2023.07.013

Embracing Change: From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease Under the Steatotic Liver Disease Umbrella
Noureddin, M, Wei, L, Castera, L & Tsochatzis, EA 2024, , Clinical Gastroenterology and Hepatology, vol. 22, no. 1, pp. 9-11. https://doi.org/10.1016/j.cgh.2023.09.034

MEFIB vs. MAST and FAST: Not a competition but useful tools
Noureddin, M, Harrison, SA & Alkhouri, N 2024, , Journal of Hepatology, vol. 80, no. 1, pp. e35-e36. https://doi.org/10.1016/j.jhep.2022.10.020

A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
Alkhouri, N, Edwards, K, Berman, M, Finn, H, Escandon, R, Lupinacci, P, Guthrie, N, Coste, A, Topete, J & Noureddin, M 2024, , Gastro Hep Advances, vol. 3, no. 1, pp. 9-16. https://doi.org/10.1016/j.gastha.2023.08.019

COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States
Kaur, B, Yeo, YH, Liang, J, Luu, M, Ayoub, W, Kuo, A, Trivedi, H, Sankar, K, Gong, J, Hendifar, A, Osipov, A, Kosari, K, Nissen, N, Noureddin, M, Singal, AG & Yang, JD 2024, , Gastro Hep Advances, vol. 3, no. 2, pp. 230-237. https://doi.org/10.1016/j.gastha.2023.11.011

Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis
Lim, WH, Tay, P, Ng, CH, Tan, DJH, Ong, C, Koh, JH, Teng, M, Chee, D, Wong, ZY, Kawaguchi, T, Takahashi, H, Muthiah, M, Tan, EXX, Wijarnpreecha, K, Lee, GH, Noureddin, M, Lee, BP, Mathurin, P, Loomba, R & Huang, DQ 2024, , Alimentary Pharmacology and Therapeutics, vol. 59, no. 6, pp. 730-741. https://doi.org/10.1111/apt.17888

VIEW FULL PUBLICATIONS